Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the must-buy penny stocks to invest in now. Recursion Pharmaceuticals ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...

Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research collaboration may initiate up to seven oncology ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, ...

Recursion Pharmaceuticals (NASDAQ: RXRX) and Exscientia (NASDAQ: EXAI) made waves on Aug. 8 when they announced plans to merge into one business, forming the world's largest biotech devoted to doing ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know. RXRX is hovering near ...